HC Wainwright & Co. Reiterates Neutral on Aclaris Therapeutics
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Neutral rating on Aclaris Therapeutics (NASDAQ:ACRS).

August 19, 2024 | 12:18 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. has reiterated its Neutral rating on Aclaris Therapeutics (NASDAQ:ACRS).
The reiteration of a Neutral rating suggests that the analyst does not see significant upside or downside potential in the short term. This is likely to result in a neutral impact on the stock price.
CONFIDENCE 90
IMPORTANCE 50
RELEVANCE 100